Artwork

Content provided by Cambridge Healthtech Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Cambridge Healthtech Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Episode: 45 - Advances in Targeted Protein Degradation

30:16
 
Share
 

Manage episode 355344476 series 2967424
Content provided by Cambridge Healthtech Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Cambridge Healthtech Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this month’s episode of the Chain, Jim Wells, professor of pharmaceutical chemistry and cellular and molecular pharmacology at the University of California, San Francisco, sits down with moderator Ben Hackel, associate professor of chemical engineering and materials science at the University of Minnesota, to discuss Wells’ work in advancing targeted protein degradation.

Wells outlines the key design elements of targeted protein degraders and their general mechanism of action, how his lab developed antibody-based PROTACs—also known as AbTACs—to target extracellular proteins, and the innovative work from industry leaders that inspired his lab’s discoveries. He also speaks about the lingering questions driving ongoing and future projects, the challenges facing the protein degradation space, and why he considers himself a “pirate of biology” rather than an inventor.

Links from this episode:
University of California, San Francisco
University of Minnesota
Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1
PEGSBoston Conference and Expo

  continue reading

65 episodes

Artwork
iconShare
 
Manage episode 355344476 series 2967424
Content provided by Cambridge Healthtech Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Cambridge Healthtech Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this month’s episode of the Chain, Jim Wells, professor of pharmaceutical chemistry and cellular and molecular pharmacology at the University of California, San Francisco, sits down with moderator Ben Hackel, associate professor of chemical engineering and materials science at the University of Minnesota, to discuss Wells’ work in advancing targeted protein degradation.

Wells outlines the key design elements of targeted protein degraders and their general mechanism of action, how his lab developed antibody-based PROTACs—also known as AbTACs—to target extracellular proteins, and the innovative work from industry leaders that inspired his lab’s discoveries. He also speaks about the lingering questions driving ongoing and future projects, the challenges facing the protein degradation space, and why he considers himself a “pirate of biology” rather than an inventor.

Links from this episode:
University of California, San Francisco
University of Minnesota
Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1
PEGSBoston Conference and Expo

  continue reading

65 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide